Cargando…
Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472201/ https://www.ncbi.nlm.nih.gov/pubmed/22591909 http://dx.doi.org/10.1186/1477-7819-10-82 |
_version_ | 1782246547681968128 |
---|---|
author | Cossetti, Rachel Jorge D Bezerra, Regis Otaviano França Gumz, Brenda Telles, Adriana Costa, Frederico P |
author_facet | Cossetti, Rachel Jorge D Bezerra, Regis Otaviano França Gumz, Brenda Telles, Adriana Costa, Frederico P |
author_sort | Cossetti, Rachel Jorge D |
collection | PubMed |
description | Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs. |
format | Online Article Text |
id | pubmed-3472201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34722012012-10-17 Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases Cossetti, Rachel Jorge D Bezerra, Regis Otaviano França Gumz, Brenda Telles, Adriana Costa, Frederico P World J Surg Oncol Case Report Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs. BioMed Central 2012-05-16 /pmc/articles/PMC3472201/ /pubmed/22591909 http://dx.doi.org/10.1186/1477-7819-10-82 Text en Copyright ©2012 Cossetti et al.; licensee BioMed Central Ltd http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Cossetti, Rachel Jorge D Bezerra, Regis Otaviano França Gumz, Brenda Telles, Adriana Costa, Frederico P Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title | Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title_full | Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title_fullStr | Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title_full_unstemmed | Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title_short | Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases |
title_sort | whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with octreoscan® in two cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472201/ https://www.ncbi.nlm.nih.gov/pubmed/22591909 http://dx.doi.org/10.1186/1477-7819-10-82 |
work_keys_str_mv | AT cossettiracheljorged wholebodydiffusionformetastaticdiseaseassessmentinneuroendocrinecarcinomascomparisonwithoctreoscanintwocases AT bezerraregisotavianofranca wholebodydiffusionformetastaticdiseaseassessmentinneuroendocrinecarcinomascomparisonwithoctreoscanintwocases AT gumzbrenda wholebodydiffusionformetastaticdiseaseassessmentinneuroendocrinecarcinomascomparisonwithoctreoscanintwocases AT tellesadriana wholebodydiffusionformetastaticdiseaseassessmentinneuroendocrinecarcinomascomparisonwithoctreoscanintwocases AT costafredericop wholebodydiffusionformetastaticdiseaseassessmentinneuroendocrinecarcinomascomparisonwithoctreoscanintwocases |